nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS2—Risedronate—osteoporosis	0.735	1	CbGbCtD
Nepafenac—Iritis—Ibandronate—osteoporosis	0.00777	0.0297	CcSEcCtD
Nepafenac—Sensation of foreign body—Ethinyl Estradiol—osteoporosis	0.00766	0.0292	CcSEcCtD
Nepafenac—Impaired healing—Alendronate—osteoporosis	0.00701	0.0268	CcSEcCtD
Nepafenac—Iritis—Risedronate—osteoporosis	0.0064	0.0244	CcSEcCtD
Nepafenac—Bleeding time prolonged—Conjugated Estrogens—osteoporosis	0.0064	0.0244	CcSEcCtD
Nepafenac—Endophthalmitis—Ibandronate—osteoporosis	0.0062	0.0237	CcSEcCtD
Nepafenac—Iritis—Pamidronate—osteoporosis	0.00609	0.0232	CcSEcCtD
Nepafenac—Iritis—Zoledronate—osteoporosis	0.00556	0.0212	CcSEcCtD
Nepafenac—Eye pruritus—Pamidronate—osteoporosis	0.00517	0.0198	CcSEcCtD
Nepafenac—Endophthalmitis—Risedronate—osteoporosis	0.00511	0.0195	CcSEcCtD
Nepafenac—Ocular hyperaemia—Zoledronate—osteoporosis	0.00451	0.0172	CcSEcCtD
Nepafenac—Endophthalmitis—Zoledronate—osteoporosis	0.00444	0.0169	CcSEcCtD
Nepafenac—Dermatitis atopic—Ibandronate—osteoporosis	0.00399	0.0152	CcSEcCtD
Nepafenac—Ocular hyperaemia—Estradiol—osteoporosis	0.00347	0.0133	CcSEcCtD
Nepafenac—Endophthalmitis—Estradiol—osteoporosis	0.00342	0.0131	CcSEcCtD
Nepafenac—Dermatitis atopic—Risedronate—osteoporosis	0.00329	0.0126	CcSEcCtD
Nepafenac—Cataract—Ibandronate—osteoporosis	0.0031	0.0118	CcSEcCtD
Nepafenac—Blood pressure increased—Estropipate—osteoporosis	0.00308	0.0118	CcSEcCtD
Nepafenac—Blood pressure increased—Raloxifene—osteoporosis	0.00298	0.0114	CcSEcCtD
Nepafenac—Photophobia—Calcitriol—osteoporosis	0.00271	0.0104	CcSEcCtD
Nepafenac—Arthritis—Etidronic acid—osteoporosis	0.00266	0.0102	CcSEcCtD
Nepafenac—Blepharitis—Estradiol—osteoporosis	0.00265	0.0101	CcSEcCtD
Nepafenac—Cataract—Risedronate—osteoporosis	0.00256	0.00976	CcSEcCtD
Nepafenac—Blood pressure increased—Ethinyl Estradiol—osteoporosis	0.0025	0.00953	CcSEcCtD
Nepafenac—Diabetes mellitus—Raloxifene—osteoporosis	0.00249	0.0095	CcSEcCtD
Nepafenac—Dry eye—Risedronate—osteoporosis	0.00225	0.00858	CcSEcCtD
Nepafenac—Arthritis—Raloxifene—osteoporosis	0.00223	0.00851	CcSEcCtD
Nepafenac—Cataract—Zoledronate—osteoporosis	0.00222	0.00848	CcSEcCtD
Nepafenac—Arthritis—Ibandronate—osteoporosis	0.00221	0.00842	CcSEcCtD
Nepafenac—Blood pressure increased—Conjugated Estrogens—osteoporosis	0.00203	0.00777	CcSEcCtD
Nepafenac—Eye irritation—Estradiol—osteoporosis	0.00191	0.00728	CcSEcCtD
Nepafenac—Arthritis—Risedronate—osteoporosis	0.00182	0.00694	CcSEcCtD
Nepafenac—Hypertension—Ergocalciferol—osteoporosis	0.00181	0.0069	CcSEcCtD
Nepafenac—Eye pain—Zoledronate—osteoporosis	0.0017	0.00649	CcSEcCtD
Nepafenac—Blood pressure increased—Estradiol—osteoporosis	0.00163	0.00622	CcSEcCtD
Nepafenac—Sinusitis—Estropipate—osteoporosis	0.00162	0.00617	CcSEcCtD
Nepafenac—Arthritis—Zoledronate—osteoporosis	0.00158	0.00603	CcSEcCtD
Nepafenac—Sinusitis—Raloxifene—osteoporosis	0.00157	0.00598	CcSEcCtD
Nepafenac—Dry eye—Estradiol—osteoporosis	0.0015	0.00574	CcSEcCtD
Nepafenac—Eye disorder—Estropipate—osteoporosis	0.00145	0.00552	CcSEcCtD
Nepafenac—Hypersensitivity—Calcium Acetate—osteoporosis	0.00143	0.00544	CcSEcCtD
Nepafenac—Angiopathy—Estropipate—osteoporosis	0.0014	0.00536	CcSEcCtD
Nepafenac—Immune system disorder—Estropipate—osteoporosis	0.0014	0.00533	CcSEcCtD
Nepafenac—Eye disorder—Ibandronate—osteoporosis	0.00139	0.00529	CcSEcCtD
Nepafenac—Pruritus—Calcium Acetate—osteoporosis	0.00137	0.00523	CcSEcCtD
Nepafenac—Angiopathy—Raloxifene—osteoporosis	0.00136	0.00519	CcSEcCtD
Nepafenac—Angiopathy—Ibandronate—osteoporosis	0.00135	0.00514	CcSEcCtD
Nepafenac—Immune system disorder—Ibandronate—osteoporosis	0.00134	0.00511	CcSEcCtD
Nepafenac—Sinusitis—Ethinyl Estradiol—osteoporosis	0.00131	0.005	CcSEcCtD
Nepafenac—Dizziness—Calcium Acetate—osteoporosis	0.00128	0.00488	CcSEcCtD
Nepafenac—Sinusitis—Risedronate—osteoporosis	0.00128	0.00488	CcSEcCtD
Nepafenac—Vomiting—Calcium Acetate—osteoporosis	0.00123	0.0047	CcSEcCtD
Nepafenac—Arthritis—Estradiol—osteoporosis	0.00122	0.00464	CcSEcCtD
Nepafenac—Sinusitis—Pamidronate—osteoporosis	0.00121	0.00464	CcSEcCtD
Nepafenac—Eye disorder—Ethinyl Estradiol—osteoporosis	0.00117	0.00447	CcSEcCtD
Nepafenac—Nausea—Calcium Acetate—osteoporosis	0.00115	0.00439	CcSEcCtD
Nepafenac—Eye disorder—Risedronate—osteoporosis	0.00114	0.00436	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00114	0.00435	CcSEcCtD
Nepafenac—Angiopathy—Ethinyl Estradiol—osteoporosis	0.00114	0.00434	CcSEcCtD
Nepafenac—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00113	0.00432	CcSEcCtD
Nepafenac—Hypertension—Ibandronate—osteoporosis	0.00111	0.00426	CcSEcCtD
Nepafenac—Angiopathy—Risedronate—osteoporosis	0.00111	0.00423	CcSEcCtD
Nepafenac—Immune system disorder—Risedronate—osteoporosis	0.0011	0.00421	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.0011	0.00421	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00109	0.00417	CcSEcCtD
Nepafenac—Hypertension—Calcitriol—osteoporosis	0.00109	0.00417	CcSEcCtD
Nepafenac—Eye disorder—Pamidronate—osteoporosis	0.00109	0.00415	CcSEcCtD
Nepafenac—Nervous system disorder—Estropipate—osteoporosis	0.00108	0.00411	CcSEcCtD
Nepafenac—Dry mouth—Ibandronate—osteoporosis	0.00107	0.0041	CcSEcCtD
Nepafenac—Sinusitis—Conjugated Estrogens—osteoporosis	0.00107	0.00408	CcSEcCtD
Nepafenac—Skin disorder—Estropipate—osteoporosis	0.00107	0.00407	CcSEcCtD
Nepafenac—Angiopathy—Pamidronate—osteoporosis	0.00105	0.00402	CcSEcCtD
Nepafenac—Dry mouth—Calcitriol—osteoporosis	0.00105	0.00402	CcSEcCtD
Nepafenac—Immune system disorder—Pamidronate—osteoporosis	0.00105	0.00401	CcSEcCtD
Nepafenac—Nervous system disorder—Raloxifene—osteoporosis	0.00104	0.00398	CcSEcCtD
Nepafenac—Skin disorder—Raloxifene—osteoporosis	0.00103	0.00395	CcSEcCtD
Nepafenac—Nervous system disorder—Ibandronate—osteoporosis	0.00103	0.00394	CcSEcCtD
Nepafenac—Skin disorder—Ibandronate—osteoporosis	0.00102	0.00391	CcSEcCtD
Nepafenac—Nausea—Ergocalciferol—osteoporosis	0.00101	0.00388	CcSEcCtD
Nepafenac—Skin disorder—Calcitriol—osteoporosis	0.001	0.00382	CcSEcCtD
Nepafenac—Eye disorder—Zoledronate—osteoporosis	0.000992	0.00379	CcSEcCtD
Nepafenac—Angiopathy—Zoledronate—osteoporosis	0.000963	0.00368	CcSEcCtD
Nepafenac—Immune system disorder—Zoledronate—osteoporosis	0.000958	0.00366	CcSEcCtD
Nepafenac—Eye disorder—Conjugated Estrogens—osteoporosis	0.000955	0.00365	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Estropipate—osteoporosis	0.000948	0.00362	CcSEcCtD
Nepafenac—Hypersensitivity—Etidronic acid—osteoporosis	0.000936	0.00357	CcSEcCtD
Nepafenac—Angiopathy—Conjugated Estrogens—osteoporosis	0.000927	0.00354	CcSEcCtD
Nepafenac—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000923	0.00352	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000922	0.00352	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000919	0.00351	CcSEcCtD
Nepafenac—Hypertension—Risedronate—osteoporosis	0.000918	0.00351	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000909	0.00347	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000899	0.00343	CcSEcCtD
Nepafenac—Pruritus—Etidronic acid—osteoporosis	0.000898	0.00343	CcSEcCtD
Nepafenac—Dry mouth—Risedronate—osteoporosis	0.000886	0.00338	CcSEcCtD
Nepafenac—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000873	0.00333	CcSEcCtD
Nepafenac—Hypertension—Pamidronate—osteoporosis	0.000873	0.00333	CcSEcCtD
Nepafenac—Vision blurred—Zoledronate—osteoporosis	0.000871	0.00332	CcSEcCtD
Nepafenac—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000865	0.0033	CcSEcCtD
Nepafenac—Sinusitis—Estradiol—osteoporosis	0.000855	0.00326	CcSEcCtD
Nepafenac—Nervous system disorder—Risedronate—osteoporosis	0.000851	0.00325	CcSEcCtD
Nepafenac—Skin disorder—Risedronate—osteoporosis	0.000843	0.00322	CcSEcCtD
Nepafenac—Vision blurred—Conjugated Estrogens—osteoporosis	0.000838	0.0032	CcSEcCtD
Nepafenac—Hypersensitivity—Estropipate—osteoporosis	0.000809	0.00309	CcSEcCtD
Nepafenac—Nervous system disorder—Pamidronate—osteoporosis	0.000809	0.00309	CcSEcCtD
Nepafenac—Vomiting—Etidronic acid—osteoporosis	0.000807	0.00308	CcSEcCtD
Nepafenac—Hypertension—Zoledronate—osteoporosis	0.000797	0.00305	CcSEcCtD
Nepafenac—Hypersensitivity—Alendronate—osteoporosis	0.000797	0.00304	CcSEcCtD
Nepafenac—Headache—Etidronic acid—osteoporosis	0.000796	0.00304	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000781	0.00298	CcSEcCtD
Nepafenac—Pruritus—Estropipate—osteoporosis	0.000777	0.00297	CcSEcCtD
Nepafenac—Hypersensitivity—Ibandronate—osteoporosis	0.000776	0.00296	CcSEcCtD
Nepafenac—Dry mouth—Zoledronate—osteoporosis	0.000769	0.00294	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000769	0.00294	CcSEcCtD
Nepafenac—Pruritus—Alendronate—osteoporosis	0.000766	0.00292	CcSEcCtD
Nepafenac—Eye disorder—Estradiol—osteoporosis	0.000764	0.00292	CcSEcCtD
Nepafenac—Hypersensitivity—Calcitriol—osteoporosis	0.00076	0.0029	CcSEcCtD
Nepafenac—Nausea—Etidronic acid—osteoporosis	0.000754	0.00288	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000752	0.00287	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Risedronate—osteoporosis	0.00075	0.00286	CcSEcCtD
Nepafenac—Pruritus—Ibandronate—osteoporosis	0.000745	0.00285	CcSEcCtD
Nepafenac—Angiopathy—Estradiol—osteoporosis	0.000742	0.00283	CcSEcCtD
Nepafenac—Nervous system disorder—Zoledronate—osteoporosis	0.000739	0.00282	CcSEcCtD
Nepafenac—Immune system disorder—Estradiol—osteoporosis	0.000739	0.00282	CcSEcCtD
Nepafenac—Skin disorder—Zoledronate—osteoporosis	0.000732	0.0028	CcSEcCtD
Nepafenac—Pruritus—Calcitriol—osteoporosis	0.00073	0.00279	CcSEcCtD
Nepafenac—Dizziness—Estropipate—osteoporosis	0.000726	0.00277	CcSEcCtD
Nepafenac—Dizziness—Alendronate—osteoporosis	0.000716	0.00273	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000713	0.00272	CcSEcCtD
Nepafenac—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000712	0.00272	CcSEcCtD
Nepafenac—Skin disorder—Conjugated Estrogens—osteoporosis	0.000705	0.00269	CcSEcCtD
Nepafenac—Dizziness—Raloxifene—osteoporosis	0.000704	0.00269	CcSEcCtD
Nepafenac—Vomiting—Estropipate—osteoporosis	0.000698	0.00267	CcSEcCtD
Nepafenac—Dizziness—Ibandronate—osteoporosis	0.000697	0.00266	CcSEcCtD
Nepafenac—Headache—Estropipate—osteoporosis	0.000688	0.00263	CcSEcCtD
Nepafenac—Vomiting—Alendronate—osteoporosis	0.000688	0.00263	CcSEcCtD
Nepafenac—Headache—Alendronate—osteoporosis	0.000678	0.00259	CcSEcCtD
Nepafenac—Vomiting—Raloxifene—osteoporosis	0.000677	0.00258	CcSEcCtD
Nepafenac—Vomiting—Ibandronate—osteoporosis	0.00067	0.00256	CcSEcCtD
Nepafenac—Headache—Raloxifene—osteoporosis	0.000667	0.00255	CcSEcCtD
Nepafenac—Headache—Ibandronate—osteoporosis	0.00066	0.00252	CcSEcCtD
Nepafenac—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000656	0.00251	CcSEcCtD
Nepafenac—Vomiting—Calcitriol—osteoporosis	0.000656	0.0025	CcSEcCtD
Nepafenac—Nausea—Estropipate—osteoporosis	0.000653	0.00249	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000651	0.00249	CcSEcCtD
Nepafenac—Headache—Calcitriol—osteoporosis	0.000646	0.00247	CcSEcCtD
Nepafenac—Nausea—Alendronate—osteoporosis	0.000643	0.00245	CcSEcCtD
Nepafenac—Hypersensitivity—Risedronate—osteoporosis	0.00064	0.00244	CcSEcCtD
Nepafenac—Nausea—Raloxifene—osteoporosis	0.000632	0.00241	CcSEcCtD
Nepafenac—Pruritus—Ethinyl Estradiol—osteoporosis	0.00063	0.00241	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000627	0.00239	CcSEcCtD
Nepafenac—Nausea—Ibandronate—osteoporosis	0.000626	0.00239	CcSEcCtD
Nepafenac—Hypertension—Estradiol—osteoporosis	0.000615	0.00235	CcSEcCtD
Nepafenac—Pruritus—Risedronate—osteoporosis	0.000614	0.00235	CcSEcCtD
Nepafenac—Nausea—Calcitriol—osteoporosis	0.000613	0.00234	CcSEcCtD
Nepafenac—Hypersensitivity—Pamidronate—osteoporosis	0.000608	0.00232	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000602	0.0023	CcSEcCtD
Nepafenac—Dry mouth—Estradiol—osteoporosis	0.000593	0.00226	CcSEcCtD
Nepafenac—Dizziness—Ethinyl Estradiol—osteoporosis	0.000589	0.00225	CcSEcCtD
Nepafenac—Pruritus—Pamidronate—osteoporosis	0.000584	0.00223	CcSEcCtD
Nepafenac—Dizziness—Risedronate—osteoporosis	0.000574	0.00219	CcSEcCtD
Nepafenac—Nervous system disorder—Estradiol—osteoporosis	0.00057	0.00218	CcSEcCtD
Nepafenac—Vomiting—Ethinyl Estradiol—osteoporosis	0.000566	0.00216	CcSEcCtD
Nepafenac—Skin disorder—Estradiol—osteoporosis	0.000564	0.00215	CcSEcCtD
Nepafenac—Headache—Ethinyl Estradiol—osteoporosis	0.000558	0.00213	CcSEcCtD
Nepafenac—Hypersensitivity—Zoledronate—osteoporosis	0.000555	0.00212	CcSEcCtD
Nepafenac—Vomiting—Risedronate—osteoporosis	0.000552	0.00211	CcSEcCtD
Nepafenac—Dizziness—Pamidronate—osteoporosis	0.000546	0.00208	CcSEcCtD
Nepafenac—Headache—Risedronate—osteoporosis	0.000544	0.00208	CcSEcCtD
Nepafenac—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000535	0.00204	CcSEcCtD
Nepafenac—Pruritus—Zoledronate—osteoporosis	0.000533	0.00204	CcSEcCtD
Nepafenac—Nausea—Ethinyl Estradiol—osteoporosis	0.000529	0.00202	CcSEcCtD
Nepafenac—Vomiting—Pamidronate—osteoporosis	0.000525	0.002	CcSEcCtD
Nepafenac—Headache—Pamidronate—osteoporosis	0.000517	0.00197	CcSEcCtD
Nepafenac—Nausea—Risedronate—osteoporosis	0.000516	0.00197	CcSEcCtD
Nepafenac—Pruritus—Conjugated Estrogens—osteoporosis	0.000514	0.00196	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Estradiol—osteoporosis	0.000502	0.00192	CcSEcCtD
Nepafenac—Dizziness—Zoledronate—osteoporosis	0.000499	0.0019	CcSEcCtD
Nepafenac—Nausea—Pamidronate—osteoporosis	0.00049	0.00187	CcSEcCtD
Nepafenac—Dizziness—Conjugated Estrogens—osteoporosis	0.00048	0.00183	CcSEcCtD
Nepafenac—Vomiting—Zoledronate—osteoporosis	0.000479	0.00183	CcSEcCtD
Nepafenac—Headache—Zoledronate—osteoporosis	0.000472	0.0018	CcSEcCtD
Nepafenac—Vomiting—Conjugated Estrogens—osteoporosis	0.000462	0.00176	CcSEcCtD
Nepafenac—Headache—Conjugated Estrogens—osteoporosis	0.000455	0.00174	CcSEcCtD
Nepafenac—Nausea—Zoledronate—osteoporosis	0.000448	0.00171	CcSEcCtD
Nepafenac—Nausea—Conjugated Estrogens—osteoporosis	0.000431	0.00165	CcSEcCtD
Nepafenac—Hypersensitivity—Estradiol—osteoporosis	0.000428	0.00163	CcSEcCtD
Nepafenac—Pruritus—Estradiol—osteoporosis	0.000411	0.00157	CcSEcCtD
Nepafenac—Dizziness—Estradiol—osteoporosis	0.000384	0.00147	CcSEcCtD
Nepafenac—Vomiting—Estradiol—osteoporosis	0.000369	0.00141	CcSEcCtD
Nepafenac—Headache—Estradiol—osteoporosis	0.000364	0.00139	CcSEcCtD
Nepafenac—Nausea—Estradiol—osteoporosis	0.000345	0.00132	CcSEcCtD
Nepafenac—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—osteoporosis	0.000227	0.0742	CbGpPWpGaD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.000211	0.069	CbGpPWpGaD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.000167	0.0548	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—PRDX3—osteoporosis	0.000129	0.0421	CbGpPWpGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—NFATC1—osteoporosis	0.000119	0.039	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—PRDX3—osteoporosis	0.000102	0.0334	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	8.58e-05	0.0281	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	7.71e-05	0.0252	CbGpPWpGaD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	6.07e-05	0.0199	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—COL1A2—osteoporosis	5.36e-05	0.0175	CbGpPWpGaD
Nepafenac—PTGS1—Arachidonic acid metabolism—GPX1—osteoporosis	5.24e-05	0.0171	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—WNT1—osteoporosis	4.87e-05	0.0159	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—CYP27A1—osteoporosis	4.56e-05	0.0149	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	4.54e-05	0.0149	CbGpPWpGaD
Nepafenac—PTGS1—Overview of nanoparticle effects—TNF—osteoporosis	4.52e-05	0.0148	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	4.51e-05	0.0148	CbGpPWpGaD
Nepafenac—PTGS2—Arachidonic acid metabolism—GPX1—osteoporosis	4.16e-05	0.0136	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	3.65e-05	0.0119	CbGpPWpGaD
Nepafenac—PTGS1—Overview of nanoparticle effects—IL6—osteoporosis	3.64e-05	0.0119	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—TNF—osteoporosis	3.59e-05	0.0117	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—SOD2—osteoporosis	3.49e-05	0.0114	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—GPX1—osteoporosis	3.33e-05	0.0109	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—MTHFR—osteoporosis	3.08e-05	0.0101	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	3.05e-05	0.00997	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—IL6—osteoporosis	2.89e-05	0.00947	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	2.89e-05	0.00946	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—SOD2—osteoporosis	2.77e-05	0.00908	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.71e-05	0.00887	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	2.71e-05	0.00885	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	2.65e-05	0.00866	CbGpPWpGaD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	2.46e-05	0.00806	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	2.44e-05	0.00799	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	2.42e-05	0.00792	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—CYP19A1—osteoporosis	2.4e-05	0.00784	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	2.29e-05	0.00751	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	2.25e-05	0.00735	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	2.19e-05	0.00717	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	1.93e-05	0.0063	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	1.9e-05	0.00621	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL1B—osteoporosis	1.83e-05	0.00597	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—LEP—osteoporosis	1.8e-05	0.00588	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	1.78e-05	0.00584	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	1.77e-05	0.00578	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	1.75e-05	0.00573	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	1.74e-05	0.00569	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	1.65e-05	0.00541	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.49e-05	0.00487	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	1.45e-05	0.00474	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—POMC—osteoporosis	1.44e-05	0.00471	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	1.39e-05	0.00455	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PKM—osteoporosis	1.36e-05	0.00444	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—FDPS—osteoporosis	1.36e-05	0.00444	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—TNF—osteoporosis	1.32e-05	0.00434	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PGLS—osteoporosis	1.29e-05	0.00421	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GPD2—osteoporosis	1.29e-05	0.00421	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PKM—osteoporosis	1.29e-05	0.00421	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SOST—osteoporosis	1.29e-05	0.00421	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ANTXR2—osteoporosis	1.22e-05	0.00399	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PGLS—osteoporosis	1.22e-05	0.00399	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.18e-05	0.00387	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ATIC—osteoporosis	1.18e-05	0.00385	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PNP—osteoporosis	1.18e-05	0.00385	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	1.17e-05	0.00383	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	1.17e-05	0.00382	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	1.15e-05	0.00375	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—FDPS—osteoporosis	1.08e-05	0.00353	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PKM—osteoporosis	1.08e-05	0.00353	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL6—osteoporosis	1.07e-05	0.0035	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	1.05e-05	0.00344	CbGpPWpGaD
Nepafenac—PTGS2—Disease—GSN—osteoporosis	1.04e-05	0.00339	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PGLS—osteoporosis	1.02e-05	0.00334	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GPD2—osteoporosis	1.02e-05	0.00334	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.01e-05	0.00331	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—OXCT1—osteoporosis	1e-05	0.00327	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA2—osteoporosis	1e-05	0.00327	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MGLL—osteoporosis	9.75e-06	0.00319	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PNP—osteoporosis	9.34e-06	0.00306	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ATIC—osteoporosis	9.34e-06	0.00306	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.2e-06	0.00301	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LRP5—osteoporosis	9.02e-06	0.00295	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MYC—osteoporosis	8.93e-06	0.00292	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	8.91e-06	0.00291	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LRP6—osteoporosis	8.63e-06	0.00282	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	8.49e-06	0.00278	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TNF—osteoporosis	8.32e-06	0.00272	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—IDH2—osteoporosis	8.29e-06	0.00271	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RPL24—osteoporosis	8.29e-06	0.00271	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LTF—osteoporosis	8.29e-06	0.00271	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA2—osteoporosis	7.95e-06	0.0026	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—OXCT1—osteoporosis	7.95e-06	0.0026	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP27A1—osteoporosis	7.8e-06	0.00255	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MGLL—osteoporosis	7.74e-06	0.00253	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ACP5—osteoporosis	7.59e-06	0.00248	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.49e-06	0.00245	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.3e-06	0.00239	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ACP5—osteoporosis	7.19e-06	0.00235	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TPI1—osteoporosis	7.05e-06	0.00231	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL6—osteoporosis	6.71e-06	0.0022	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TPI1—osteoporosis	6.68e-06	0.00219	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—P4HB—osteoporosis	6.63e-06	0.00217	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—IDH2—osteoporosis	6.58e-06	0.00215	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GAPDH—osteoporosis	6.51e-06	0.00213	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—RAP1A—osteoporosis	6.34e-06	0.00207	CbGpPWpGaD
Nepafenac—PTGS2—Disease—P4HB—osteoporosis	6.28e-06	0.00206	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP27A1—osteoporosis	6.19e-06	0.00203	CbGpPWpGaD
Nepafenac—PTGS2—Disease—GAPDH—osteoporosis	6.17e-06	0.00202	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	6.07e-06	0.00199	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	6.06e-06	0.00198	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ACP5—osteoporosis	6.02e-06	0.00197	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.95e-06	0.00195	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NFATC1—osteoporosis	5.86e-06	0.00192	CbGpPWpGaD
Nepafenac—PTGS2—Disease—DKK1—osteoporosis	5.82e-06	0.0019	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	5.66e-06	0.00185	CbGpPWpGaD
Nepafenac—PTGS2—Disease—WNT1—osteoporosis	5.6e-06	0.00183	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TPI1—osteoporosis	5.6e-06	0.00183	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.53e-06	0.00181	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGA—osteoporosis	5.45e-06	0.00178	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—P4HB—osteoporosis	5.26e-06	0.00172	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GAPDH—osteoporosis	5.17e-06	0.00169	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ENO1—osteoporosis	5.12e-06	0.00168	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PSMA2—osteoporosis	5.05e-06	0.00165	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PSMA5—osteoporosis	5.05e-06	0.00165	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—RAP1A—osteoporosis	5.03e-06	0.00165	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ENO1—osteoporosis	4.86e-06	0.00159	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PSMA5—osteoporosis	4.79e-06	0.00157	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PSMA2—osteoporosis	4.79e-06	0.00157	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CALCA—osteoporosis	4.46e-06	0.00146	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.39e-06	0.00144	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP19A1—osteoporosis	4.1e-06	0.00134	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ENO1—osteoporosis	4.07e-06	0.00133	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KL—osteoporosis	4.05e-06	0.00133	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PSMA2—osteoporosis	4.01e-06	0.00131	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PSMA5—osteoporosis	4.01e-06	0.00131	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ADCY5—osteoporosis	3.35e-06	0.0011	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GPX1—osteoporosis	3.34e-06	0.00109	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP19A1—osteoporosis	3.25e-06	0.00106	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ADCY5—osteoporosis	3.17e-06	0.00104	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MTHFR—osteoporosis	3.08e-06	0.00101	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTHFR—osteoporosis	2.92e-06	0.000955	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IRS2—osteoporosis	2.78e-06	0.000908	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ADCY5—osteoporosis	2.66e-06	0.000869	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GPX1—osteoporosis	2.65e-06	0.000866	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—POMC—osteoporosis	2.46e-06	0.000805	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTHFR—osteoporosis	2.44e-06	0.0008	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IRS1—osteoporosis	2.42e-06	0.000793	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6R—osteoporosis	2.28e-06	0.000745	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—POMC—osteoporosis	1.95e-06	0.000639	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MYC—osteoporosis	1.35e-06	0.000441	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFB1—osteoporosis	1.35e-06	0.00044	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6—osteoporosis	1.01e-06	0.000332	CbGpPWpGaD
